We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Liver Transplantation and Uveal Malignant Melanoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01311466
First Posted: March 9, 2011
Last Update Posted: March 31, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Svein Dueland, Oslo University Hospital
  Purpose
Patients with uveal malignatnt melanoma with liver metastases have a dismal prognosis with a median survival of less than 12 months. There is noe established treatment showing increased overall survival. In this study we will determin if liver transplantation will result in long term survival in patients with liver only metastases from uveal malignant melanoma.

Condition Intervention Phase
Uveal Malignant Melanoma Procedure: Liver transplantation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Svein Dueland, Oslo University Hospital:

Primary Outcome Measures:
  • Over all survival

Enrollment: 2
Study Start Date: January 2011
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liver transplantation Procedure: Liver transplantation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:Uveal malignant melanoma, liver only metastases, ECOG 0-1 -

Exclusion Criteria:Extra hepatic disease, previous other maligency, previous organ transplantation

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01311466


Locations
Norway
Oslo University Hospital
Oslo, Norway, N0310
Sponsors and Collaborators
Oslo University Hospital
  More Information

Responsible Party: Svein Dueland, MD PhD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01311466     History of Changes
Other Study ID Numbers: S-06408
First Submitted: March 7, 2011
First Posted: March 9, 2011
Last Update Posted: March 31, 2016
Last Verified: March 2016

Keywords provided by Svein Dueland, Oslo University Hospital:
Liver transplantation
Overall survival

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Liver Extracts
Hematinics